Core Insights - Fennec Pharmaceuticals has presented new real-world data supporting the use of PEDMARK (sodium thiosulfate injection) in adults with head and neck cancers, indicating its safe administration at least six hours after cisplatin treatment without compromising the drug's antitumor efficacy [1][2][5] - The findings highlight the potential of PEDMARK to mitigate cisplatin-induced hearing loss, a significant survivorship issue, with most high-risk patients showing no measurable hearing loss during or after treatment [1][4][5] Company Overview - Fennec Pharmaceuticals is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients, having received FDA approval in September 2022 and subsequent approvals in Europe and the UK [22][24] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the UK, Australia, and New Zealand [23] Industry Context - Cisplatin is widely used in treating solid tumors but is associated with a high incidence of hearing loss, affecting 60-90% of patients depending on treatment parameters [7][8] - The introduction of PEDMARK represents a significant advancement in addressing the long-term quality of life issues faced by cancer survivors due to treatment-induced hearing loss [12][9]

Core Insights - Fennec Pharmaceuticals is initiating a study to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors, reflecting a growing clinical interest in addressing hearing loss among cancer patients [1][4]. Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on reducing the risk of ototoxicity in cancer patients receiving cisplatin-based chemotherapy. The company has received FDA approval for PEDMARK in September 2022 and European Commission approval in June 2023 [24][25]. Study Details - The investigator-sponsored study by City of Hope will assess the addition of PEDMARK to standard cisplatin chemotherapy to reduce drug-induced ear damage in men with metastatic testicular germ cell tumors. The study is a Phase I trial (NCT07218913) [5][6]. Clinical Context - Cisplatin has significantly improved survival rates for patients with germ cell tumors, but it can lead to permanent hearing loss in up to 80% of survivors, impacting their quality of life [2][8]. The study aims to integrate hearing protection into comprehensive cancer care [4]. Product Information - PEDMARK (sodium thiosulfate injection) is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged one month and older with localized, non-metastatic solid tumors. It is also recommended for adolescent and young adult patients by the National Comprehensive Cancer Network [3][12]. Market Opportunity - Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by platinum-based chemotherapy, highlighting a significant market opportunity for PEDMARK. The incidence of ototoxicity varies between 60-90% depending on treatment specifics [13][9]. Future Collaborations - Multiple other investigator-initiated studies are under review or in advanced stages of contracting, which are expected to strengthen Fennec's clinical and commercial foundation [7].

Core Insights - Fennec Pharmaceuticals Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:00 p.m. ET, available via webcast [1][2] Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity in cancer patients [3] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3] Licensing and Commercialization - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently commercially available in the U.K. and Germany [4] Regulatory Status and Market Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents protecting PEDMARK until 2039 in both the U.S. and internationally [5]

Core Viewpoint - Fennec Pharmaceuticals Inc. is initiating a non-brokered offering of common shares in Canada at a price of US$7.50 per share, aiming for gross proceeds of up to US$5,025,000, with the offering expected to close on November 17, 2025, subject to customary closing conditions [1][2]. Offering Details - The offering targets prospective purchasers in Canada (excluding Quebec) under the listed issuer financing exemption, and the shares will not be subject to a hold period under Canadian securities laws [2][4]. - There are no guarantees regarding the completion of the offering or the total gross proceeds raised [2]. Company Background - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its product PEDMARK approved by the FDA in September 2022 and by the European Commission in June 2023 [6][8]. - The company has an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [7]. Regulatory and Market Position - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has Pediatric Use Marketing Authorization in Europe, providing significant market protection [8]. - Fennec holds patents for PEDMARK that extend until 2039 in both the U.S. and internationally, enhancing its competitive position in the market [8].

Core Points - Fennec Pharmaceuticals Inc. will release its Q2 2025 financial results on August 14, 2025, before U.S. market opening [1] - A conference call and webcast will be held on the same day to discuss financial and business results [1][2] Company Overview - Fennec Pharmaceuticals is focused on protecting cancer patients from cisplatin-induced hearing loss through its product PEDMARK, which received FDA approval in September 2022 and European Commission approval in June 2023 [3] - The product is marketed as PEDMARQSI in the U.K. and has been commercialized in the U.K. and Germany following an exclusive licensing agreement with Norgine Pharmaceuticals [4] - PEDMARK has Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [5]